Share-based Payment Arrangement, Expense of LENZ Therapeutics, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
LENZ Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • LENZ Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,469,000, a 58% increase year-over-year.
  • LENZ Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,499,000, a 100% increase year-over-year.
  • LENZ Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,365,000, a 374% increase from 2023.
  • LENZ Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,343,000, a 90% decline from 2022.
  • LENZ Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13,534,000, a 72% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

LENZ Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,499,000 $3,469,000 +$1,278,000 +58% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $9,221,000 $2,845,000 +$1,248,000 +78% 01 Apr 2025 30 Jun 2025 10-Q 30 Jul 2025 2025 Q2
Q1 2025 $7,973,000 $2,555,000 +$1,608,000 +170% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $6,365,000 $1,630,000 +$1,112,000 +215% 01 Oct 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
Q3 2024 $5,253,000 $2,191,000 +$1,697,000 +344% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $3,556,000 $1,597,000 +$1,408,000 +745% 01 Apr 2024 30 Jun 2024 10-Q 30 Jul 2025 2025 Q2
Q1 2024 $2,148,000 $947,000 +$805,000 +567% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $1,343,000 $518,000 -$3,104,000 -86% 01 Oct 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
Q3 2023 $4,447,000 $494,000 -$2,716,000 -85% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $7,163,000 $189,000 -$3,171,000 -94% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $10,334,000 $142,000 -$3,200,000 -96% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $13,534,000 $3,622,000 +$1,176,000 +48% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $12,358,000 $3,210,000 +$836,000 +35% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $11,522,000 $3,360,000 +$1,342,000 +67% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $10,180,000 $3,342,000 +$2,309,000 +224% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $7,871,000 $2,446,000 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
Q3 2021 $2,374,000 +$2,338,000 +6494% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $2,018,000 +$2,017,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,033,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $36,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $1,000* 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2

LENZ Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,365,000 +$5,022,000 +374% 01 Jan 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
2023 $1,343,000 -$12,191,000 -90% 01 Jan 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
2022 $13,534,000 +$5,663,000 +72% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $7,871,000 +$7,694,000 +4347% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 $177,000 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.